We found that serum IL-5 and IFN-γ levels were closely associated with tumor burden in metastatic NSCLC and GC patients receiving anti-PD-1 mAbs, so their expression levels can assess the efficacy of anti-PD-1 mAb treatment. Here, IFNG is linked to neoplasm.